|
Day 2
|
|
Time
|
Topic
|
Presenter
|
Moderator
|
|
SESSION 4 - PERSONALIZED MEDICINE CLINICAL APPLICATION
|
|
4pm to 4.20pm
|
Hereditary Cancer Syndromes Cancers - Qatar Experience
|
Dr. Reem Al Sulaiman
Consultant Genetic Counselor
Interim Deputy Chair Medical Genetics Department
|
Dr. Anas Ahmad Hamad,
Dr. Hind El Malik,
Dr. Abdulrahman Zar Gul
|
|
4.20pm to 4.40pm
|
Current Role of NCCCR Pharmacy in Personalized Medicine
|
Dr. Shereen Elazzazy
PharmD, MBA, BSc Pharm, NLP Dip, CACP, IPTeC
|
|
4.40pm to 5.10pm
|
Precision Medicine on HR + HER - Metastatic Breast Cancer
|
Dr. Giuseppe Curigliano, MD, Phd
Associate Professor of Medical Oncology, University of Milano, Head of the Division of Early Drug Development at the European Institute of Oncology, IRCSS, Italy
|
|
5.10pm to 5.30pm
|
Target Therapy in Colorectal Cancer
|
Dr. Kakil Ibrahim
Senior Consultant, Medical Oncology
|
|
5.30pm to 6pm
|
Long Term Outcome of Checkpoint Inhibitor in NSCLC
|
Prof. Frank Griesinger
Director of Hematology and Oncology Dept Pius Hospital, Oldenburg, Germany
Professor of Oncology at the University of Oldenburg, Germany
|
|
6pm to 6.30pm
|
Integrating New and Emerging Targeted Therapy into the Treatment of Ovarian Cancer |
Prof. Christian Marth MD, PhD
Professor Innsbruck Medical University, Austria
|
|
6.30pm to 6.45pm
|
PRAYER BREAK
|
|
6.45pm to 7.15pm
|
Molecular Profiling: where do we stand
|
Dr. David R. Gandara
Professor of Medicine
Emeritus Director, Thoracic Oncology, UC Davis Comprehensive Cancer Center, California, USA
|
|
7.15pm to 7.30pm
|
Panel Discussion
|
All Speakers
|
|
SESSION OUTCOME
|
|
7.30pm to 7.45pm
|
CLOSING REMARK
|
Dr. Salha Bujassoum Al-Bader
Senior Consultant
Chairperson Medical Oncology
|
